| Literature DB >> 26693312 |
Jet van Zalen1, Nikhil R Patel1, Steven J Podd1, Prashanth Raju1, Rob McIntosh1, Gary Brickley2, Louisa Beale2, Lydia P Sturridge1, Guy W L Lloyd1.
Abstract
Resting echocardiography measurements are poor predictors of exercise capacity and symptoms in patients with heart failure (HF). Stress echocardiography may provide additional information and can be expressed using left ventricular ejection fraction (LVEF), or diastolic parameters (E/E'), but LVEF has some major limitations. Systolic annular velocity (S') provides a measure of longitudinal systolic function, which is relatively easy to obtain and shows a good relationship with exercise capacity. The objective of this study was to investigate the relationship among S', E/E' and LVEF obtained during stress echocardiography and both mortality and hospitalisation. A secondary objective was to compare S' measured using a simplified two-wall model. A total of 80 patients with stable HF underwent exercise stress echocardiography and simultaneous cardiopulmonary exercise testing. Volumetric and tissue velocity imaging (TVI) measurements were obtained, as was peak oxygen uptake (VO2 peak). Of the total number of patients, 11 died and 22 required cardiac hospitalisation. S' at peak exertion was a powerful predictor for death and hospitalisation. Cut-off points of 5.3 cm/s for death and 5.7 cm/s for hospitalisation provided optimum sensitivity and specificity. This study suggests that, in patients with systolic HF, S' at peak exertion calculated from the averaged spectral TVI systolic velocity of six myocardial segments, or using a simplified measure of two myocardial segments, is a powerful predictor of future events and stronger than LVEF, diastolic velocities at rest or exercise and VO2 peak. Results indicate that measuring S' during exercise echocardiography might play an important role in understanding the likelihood of adverse clinical outcomes in patients with HF.Entities:
Keywords: left ventricular ejection fraction; stress echocardiography; tissue Doppler imaging
Year: 2015 PMID: 26693312 PMCID: PMC4676458 DOI: 10.1530/ERP-14-0074
Source DB: PubMed Journal: Echo Res Pract ISSN: 2055-0464
Baseline clinical characteristics. Data are expressed as mean±s.d. or as number (%) of patients
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Age (years) | 72±9 | 71±9 | 74±7 | 71±10 | 74±7 |
| Male | 51 (64%) | 44 | 7 | 39 | 12 |
| IHD | 50 (63%) | 41 | 9 | 34 | 16 |
| Hypertension | 23 (29%) | 19 | 4 | 16 | 7 |
| LBBB | 42 (53%) | 38 | 4 | 32 | 10 |
| Diabetes mellitus | 15 (19%) | 14 | 1 | 10 | 5 |
| Valvular heart disease | 9 (11%) | 7 | 2 | 6 | 3 |
| CRT | 23 (29%) | 19 | 4 | 15 | 8 |
| CABG | 16 (20%) | 15 | 1 | 11 | 5 |
| PCI | 13 (16%) | 10 | 3 | 9 | 4 |
| ACE inhibitor | 50 (63) | 42 | 8 | 32 | 18 |
| β-blocker | 57 (71%) | 49 | 8 | 43 | 14 |
| Digoxin | 8 (10%) | 7 | 1 | 6 | 2 |
| Amiodarone | 17 (21%) | 13 | 4 | 11 | 6 |
| ARB | 24 (30%) | 21 | 3 | 21* | 3 |
| Diuretic | 59 (74%) | 49 | 10 | 39* | 20 |
| Statin | 54 (68%) | 49 | 5 | 39 | 15 |
| Serum creatinine (mmol/l) | 105±35.9 | 103±34 | 121±45 | 101±32 | 118±42 |
| Serum sodium (mmol/l) | 139±3.0 | 139±3 | 140±3 | 140±3 | 139±3 |
| Resting heart rate (beats/min) | 68±15 | 67±15 | 71±16 | 68±16 | 67±11 |
| Exercise heart rate (beats/min) | 99±23 | 99±22 | 96±16 | 102±24 | 91±20 |
| Resting cardiac output (l/min) | 3.9±1.4 | 3.9±1.4 | 3.7±1.3 | 3.9±1.4 | 3.9±1.6 |
| Exercise cardiac output (l/min) | 6.7±2.2 | 6.9±2.3 | 5.4±1.6 | 6.9±2.3 | 6.3±2.0 |
*P<0.05; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; CRT, cardiac resynchronisation therapy; IHD, ischaemic heart disease; LBBB, left bundle branch block; PCI, percutaneous coronary intervention.
Mean echocardiographic, exercise and functional parameters (mean±s.d.)
|
|
|
|
|
|
|---|---|---|---|---|
| S′ at rest (cm/s) | 5.4±1.6 | 3.7±1.2 | 5.3±1.7 | 4.5±1.5 |
| S′ at exercise (cm/s) | 7.1±2.2 | 4.4±1.3 | 7.2±2.4 | 5.5±1.6 |
| LVEF at rest | 33±11 | 24±6 | 33±10 | 27±11 |
| LVEF at exercise | 40±14 | 28±8 | 39±14 | 35±13 |
| E′ at rest (cm/s) | 6.4±2.6 | 5.4±2.1 | 6.4±2.6 | 5.9±2.3 |
| E′ at exercise (cm/s) | 10.1±4.6 | 7.1±2.3 | 10.2±4.7 | 8.5±3.8 |
| E/E′ at rest | 12.6±7.4 | 18.7±9.0 | 12.6±7.9 | 15.0±7.2 |
| E/E′ at exercise | 12.1±7.2 | 18.2±7.1 | 12.2±7.7 | 14.8±6.8 |
| VO2 peak (l/min) | 1.2±0.4 | 0.94±0.3 | 1.2±0.5 | 1.1±0.3 |
| EDV | 158±59 | 180±63 | 161±61 | 162±54 |
| ESV | 108±46 | 139±56 | 109±48 | 121±49 |
| EDD | 5.8±0.8 | 6.5±0.9 | 5.8±0.8 | 6.3±0.9 |
| ESD | 4.8±0.9 | 5.6±1.4 | 4.7±1.0 | 5.6±0.9 |
| LA diameter | 3.9±0.8 | 4.4±0.6 | 3.9±0.8 | 4.2±0.6 |
| NYHA | 2.2±0.8 | 2.5±0.7 | 2.2±0.7 | 2.2±0.8 |
LVEF, left ventricular ejection fraction; S′, systolic velocity; E′, myocardial velocity early diastole; E/E′, transmitral-to-basal early diastolic velocity ratio; VO2 peak, peak oxygen uptake; EDV, end-diastolic volume; ESV, end-systolic volume; EDD, end-diastolic dimensions; ESD, end-systolic dimensions; LA, left atrium; NYHA, New York Heart Association class.
Survivors vs non-survivors or hospitalisation vs no hospitalisation P<0.01.
Survivors vs non-survivors or hospitalisation vs no hospitalisation P<0.05.
Univariate predictors of mortality and cardiac admission
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| S′ at rest (cm/s) | 0.46 (0.29–0.75) | 0.002 | S′ at rest (cm/s) | 0.67 (0.50–0.90) | 0.008 |
| S′ at exercise (cm/s) | 0.47 (0.31–0.71) | <0.0001 | S′ at exercise (cm/s) | 0.65 (0.52–0.83) | <0.0001 |
| LVEF at rest | 0.91 (0.85–0.98) | 0.01 | LVEF at rest | 0.94 (0.90–0.98) | 0.008 |
| LVEF at exercise | 0.93 (0.88–0.98) | 0.01 | E/E′ at exercise | 1.05 (1.00–1.09) | 0.04 |
| E/E′ at rest | 1.07 (1.00–1.14) | 0.03 | EDD | 1.82 (1.03–3.20) | 0.04 |
| E/E′ at exercise | 1.07 (1.01–1.12) | 0.01 | ESD | 2.23 (1.31–3.77) | 0.003 |
| VO2 peak (l/min) | 0.10 (0.01–0.76) | 0.03 | Creatinine | 1.01 (1.00–1.02) | 0.04 |
| ESV | 1.01 (1.00–1.02) | 0.05 | Diuretics | 0.23 (0.05–1.00) | 0.05 |
LVEF, left ventricular ejection fraction; S′, systolic velocity; E′, myocardial velocity early diastole; E/E′, transmitral-to-basal early diastolic velocity ratio; VO2 peak, peak oxygen uptake; ESV, end-systolic volume.
Figure 1Kaplan–Meier curves for mortality (top) and hospitalisation (bottom).